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A R T I C L E I N F O A B S T R A C T
Background: Peripheral arterial diseases could be a major burden for the health system with a wide clinical 
spectrum from asymptomatic to limb-threatening. Sudden onset of limb deteriorations represent a vascular 
emergency and need proper treatment for limb preservation and life-saving. It is still challenging to choose 
proper management to reduce morbidity and mortality, despite the various advance in diagnostic and therapeutic 
tools were available.
Objective: This case report aimed to elaborate on the management of acute aorto-illiac occlusion with bilateral 
limb ischemia underwent direct catheter thrombolysis in an older patient.
Case Presentation: A 70-years-old man came to our hospital with a chief complaint of leg pain in both of his legs, 
suddenly since 18 hours before admission. He had paresthesia and paralysis in both of his legs. And the Doppler 
ultrasonography result was occlusion proximal to the right and left common iliac artery. Then we performed 
percutaneous intra-arterial thrombolysis using streptokinase with a successful outcome of peripheral revascular-
ization but with gastrointestinal bleeding as an adverse event.
Conclusion: Despite the various advancement of diagnostic and therapeutic tools available today, Acute Limb 
Ischemia (ALI) still proceed to be related to increasing major amputation and mortality rates in 20% of patients, 
more often due to the existing comorbidities such as other atherosclerotic diseases.
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 Peripheral artery disease (PAD) is one of the burdens for the 
health system and is accountable for almost 15% of the mortality rate 
in Europe. Asymptomatic or intermittent claudication to necrosis and 
limb loss are some of the clinical signs. Acute limb ischemia (ALI) is 
defined as a sudden decrease in perfusion to the limbs that threaten 
their viability. It is a serious vascular emergency. If the onset occurs 
within 14 days, the clinical presentation is considered acute.1
 All of the metabolically active tissues of the extremities, 
including the skin, muscles, and nerves, are affected by the abrupt 
ischemia. As a result, essential recognition and rapid revascularization 
are required to preserve limb viability.2 The urgency of treatment will 
depend on the severity of the limb ischemia, evaluated utilizing the 
Rutherford clinical classification. Surgical thromboembolectomy, 
bypass, percutaneous catheter-directed thrombolysis (CDT), thrombus 
aspiration/mechanical thrombectomy (with or without thrombolysis), 
and hybrid techniques such as thrombendarterectomy are all options 
for revascularization.3
 ALI patients have a significant prevalence of complications, 
and despite early revascularization, 30-day mortality and amputation 
rates are 10 - 15%. In addition, ALI patients have a higher rate of 
significant adverse events in the hospital, such as a worsening of 
congestive heart failure, infarct myocardial event, a complication of the 
respiratory tract, and deterioration in renal function.4
2. Case Presentation
 Male, 70-years-old, come with a chief complaint of leg pain 
at both of his legs, suddenly since 18 hours before admission. The pain 
was radiating to the buttock, and accompanied by an inability to move 
his leg. Since a month ago he also complained of shortness of breath 
while doing moderate activity, with leg swelling, but no orthopnea nor 
paroxysmal nocturnal dyspnea. History of leg pain associated with 
activity before was denied. History of hypertension uncontrolled for 
more than 2 years, diabetes mellitus was denied. He usually smokes 
one pack a day.
 From the physical examination, we found out he has a 
normoweight with BMI and stable vital signs with blood pressure 
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110/70mmHg, heart rate 86x/m regular, with a regular heart sound, 
no murmur nor gallop. As a local status, we found out both of leg was 
mottled and pale, cold in palpation in the level of the upper knee for the
right leg and middle tibia for the left leg. Distal pulsation was unpalpa-
ble for both legs with paresthesia and paralysis.
 The electrocardiography showed a normal sinus rhythm with 
a heart rate 80beat per minute, frontal axis normal, horizontal axis 
clockwise rotation without ST-T changes. Meanwhile, from thorax 
roentgen, there was cardiomegaly with CTR 60% in AP position and 
increased bronchovesicular pattern in apex mid area. The laboratory 
result was shown a mild leukocytosis and increased liver enzyme 
(Table 1).
 Then we performed an emergency doppler ultrasonography 
with the result of proximal occlusion of the right and left common iliac 
artery. The patient was then diagnosed with acute limb ischemia in 
right inferior extremity grade IIA and left inferior extremity grade IIB. 
The patient was suggested to undergo surgical embolectomy antero-
grade and retrograde. But due to some reason, the surgical procedure 
cannot be done, then we planned to perform Percutaneous Intraarterial 
Thrombolysis (PIAT).
 From aortography, we found out total occlusion in the 
infrarenal aorta. And we did procedural intraarterial thrombolysis 
using streptokinase 10.000 units and heparin drip with serial monitor-
ing of fibrinogen and aPTT.
 One day after the PIAT procedure, the patient was planned 
to do an arteriography evaluation but was postponed due to a deterio-
rating renal function test. Then the evaluation procedure was done by 
Doppler ultrasonography with the result of positive blood flow to the 
distal anterior tibia artery in both legs. The patient experienced melena 
post-procedural and we stopped the administration of anticoagulant 
and antiplatelet while monitoring the bleeding, vital signs, and labora-
tory marker. 
3. Discussion
 Acute limb ischemia is caused by a sudden decrease in the 
perfusion of the limb's blood arteries. arterial disease development, 
cardiac embolization, aortic dissection or embolization, injury, 
phlegmasia cerulea dolens, hypercoagulable disorders, and iatrogenic 
consequences from vascular treatments are all possible causes. 
Common clinical presentations induced by reduced blood supply 
include pain, pallor, poikilothermia, pulselessness, paresthesia, and 
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Table 2. Stages of acute limb ischemia (ALI) according to the Rutherford classification.4
Table 1. Laboratory result taken in emergency room
APTT = activated partial thromboplastin time; INR = international 
normalized ratio; PPT = partial thromboplastin time; RBS = random 
blood sugar; SGOT = Serum glutamic oxaloacetic transaminase; SGPT 
= Serum glutamic pyruvate transaminase
Parameter Result Normal Value 
Haemoglobin 13.20 g/dL 13.4 – 17.7 g/dL 
Leukocytes 14770 /µL 4300-10300/µL 
Hematocrit 56.70 % 40 – 47 % 
Thrombocytes 197.000 /µL 142000-424000/µL 
RBS 118 g/dL <200 mg /dl 
SGOT 798 U/L 0-40 U/L 
SGPT 174 U/L 0-41 U/L 
Albumin 4.40 g/dL 3.5-5.5 
Ureum 44.1 mg/dL 16.6 – 48.5 mg/dL 
Creatinine 1.19 mg/dl <1.2mg/dl 
Sodium 137 mmol/L 136 – 145 mmol/L 
Potassium 4.57 mmol/L 3.5 – 5.0 mmol/L 
Chloride 106 mmol/L 98 – 106 mmol/L 
PPT 10.90 Sec 9.4 – 11.3 
APTT 29.20 Sec 24.6 – 30.6 
INR 1.05  < 1.5 
Stage Prognosis Findings Doppler signal 
  Sensory Loss Muscle Weakness Aterial Venous 
I Limb viable, not immediately 
threatened 
None None Audible Audible 
IIa Limb marginally threatened, 
salvageable if promptly treated 
Minimal (toes) None  Often inaudible Audible  
IIb Limb immediately threatened, 
salvageable with immediate 
revascularization 
More than toes, 
pain at rest 
Mild or moderate Inaudible  Audible  
III Limb irreversibly damaged, major 




Paralysis (rigor) Inaudible  Inaudible  
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paralysis. ALI is considered when these indications occurred in less than 
two weeks.2,5 
 Obara et all present report from Britain expressed the 
incidence rates of embolism, thrombosis in native vessels, and stent or 
graft-related thrombosis are 0.46, 0.24, and 0.10 respectively, In 
research conducted by the Swedvasc registry, the etiology of limb 
ischemia was embolic in 44%, thrombotic in 53%, and a popliteal 
artery aneurysm (PA) in 3%. Arterial embolism is characterized by the 
sudden development of ALI symptoms. While the onset and progression
condition and an immediately life-threatening condition. The patient 
with acute aortic occlusion can present with bilateral lower limb 
complaints.3
 Method and treatment of choice depended on the clinical 
presentation, particularly the presence of neurological symptoms. In 
the presence of neurological signs, urgent revascularization should be 
done. Percutaneous catheter-directed thrombolytic therapy, percutane-
ous mechanical thrombus extraction or thrombo-aspiration (with or 
without thrombolytic therapy), and surgical thrombectomy, bypass, 
and/or artery repair are all options for revascularization. In the case of 
a neurological deficit, both percutaneous mechanical and surgical 
thrombectomy is strongly recommended, although catheter-directed 
thrombolytic therapy is more appropriate in less severe cases without a 
neurological deficit. In the treatment of individuals with acute limb 
ischemia, systemic thrombolysis has no place.5
 For this patient, he already had numbness in both legs and 
paralysis in his right leg and was diagnosed as acute limb ischemic 
bilateral grade IIB. The procedure can be done based on the resource in 
our hospital was surgical thromboembolectomy or catheter-directed
of symptoms are mostly due to thrombosis, patients with pre-existing 
PAD are compensated by the establishment of collateral circulation.3,6 
 
 In this patient, at first, we hypothesized the patient had acute 
limb ischemic grade IIB bilateral due to embolic, because of the abrupt 
onset of leg pain, pallor, poikilothermia, paraesthesia, and paralysis. 
But after being confirmed through the Doppler ultrasonography 
examination, he was discovered to have a thrombus proximal to the 
iliac artery, probably in the distal abdominal aorta, causing total 
occlusion to the distal vascular. Acute aortic occlusion is an uncommon
thrombolysis. The patient finally underwent the second option using 
streptokinase. There was no complication during the procedure.
 The main preferences of percutaneous over surgical  revascu-
larization of PAD are lower morbidity, shorter length of hospital stay, 
and less inconvenience. CDT is effective, with an angiographic success 
rate was three forth of the case. While patients with Rutherford class IIb 
were inferior compare to class IIa. However, there is a standard 
treatment protocol regarding the fibrinolytic agent and dosage regimen 
in these methods. Based on Eben et al, standard fibrinolytic agent to be 
used worldwide was rt-PA and Urokinase.7
 There are some techniques for thrombolytic agent infusion 
delivery and based on Karnabatidis et, al, intra-thrombus high-dose 
bolus taken after by low-dose continuous drip, considered as the 
foremost compelling procedure. The patient should be monitored to 
distinguish any possible signs of hemorrhage, and frequent hemato-
crit/hemoglobin levels should be compared to baseline values.8 
Because fibrinogen is depleted during thrombolysis, its measurement 
could be used to predict bleeding consequences or guide thrombolytic 
agent dosage. Fibrinogen levels less than 100 mg/dL were linked to the
Table 3. Infusion protocols, technical success, clinical success, and complication rates concerning various thrombolytic agents
Agent Infusion Protocol Technical/ Clinical Success Complication 
Urokinase 250.000 IU/h in the first 2h followed by the 
infusion of 120.000 IU/h for 2 h and 60.000 
IU/h for the remaining procedure 
240.000 IU/h in the first 4h followed by the 
infusion of 120.000 IU/h for 48 h (with or 
without 250.000 IU bolus) 
Low dose regimen: 50.000 IU/h 
70% complete clot dissolution 
 
69 – 81% vessel patency 
 
65 – 85% 
Major bleeding 11% 
 
Major bleeding 5.6 – 12.5% 
 
Significantly less minor 
complication compared with 
the high-dose regimen 
Alteplase (rt-PA, t-
PA) 
Weight-based scheme: 0.001 – 0.02 mg/kg/h 
Nonweight-based scheme: 0.12 – 2.0 mg/h. 
maximum dose 40mg 
88.6 – 91.8% successful 
thrombolysis 
Major bleeding 6.1 – 6.8% 
Reteplase (r-PA) Suggested from 0.25 to 1.0 mg/h. maximum 
20IU in 24 h 
 
Low dose regimen: 0.125mg/h 
Thrombolytic success 83,8 – 
86.7% 
 
Thrombolytic success 85.3% 
Major bleeding: 13.3% in 
0.5mg/h regimen, 5.4% in 
0.25 mg/h regimen 
(statistically significant) 
Major bleeding 2.9% 
(statistically significant) 
Tenecteplase (t-NK) Bolus infusion of 1 – 5mg followed by infusion 
ranging from 0.125 – 0.5 mg/h 
Technical success 91% Major bleeding 6.3% 
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occurrence of minor and serious hemorrhagic events combined in the 
Thrombolysis in Myocardial Infarction (TIMI) II study.3,9
 For this patient, the CDT procedure used a combination of 
intra-arterial continuous infusion of streptokinase and continuous 
heparin. One day after the procedure the patient complaint of melena, 
with hemoglobin drop from 19g/dL to 12 g/dL with the fibrinogen 
value was 129mg/dL. The most common CDT consequence is bleeding, 
which affects 18% of patients. Major bleeding complications impact 
8.9% of all patients, resulting in a 4.8 percent in-hospital mortality 
rate.7
 Unfortunately, since 1994, the use of streptokinase as a 
thrombolytic drug has been discouraged in clinical practice due to its 
lower efficacy and increased antigenicity.8 In 1991, Berridge did a 
study that compared intra-arterial streptokinase with rt-PA with the 
result a significant difference between vessel patency with intra-arterial 
rt-PA achieved the best rate of asymptomatic limb salvage and lower 
amputation rate.4 There is no major complication that occurred in the 
intra-arterial rt-PA group while 15% of patients in the intra-arterial 
streptokinase group experienced major hemorrhagic.10,11 
 Recombinant tissue plasminogen activator (rt-PA) and 
urokinase was thrombolytic agent recommended, for the patient with 
ALI undergoing thrombolysis procedure, by European Society of Vascu-
lar Surgery (Class IA).3
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 As for ALI Rutherford IIB, the most proper management was 
thrombus removal. Another method alternative for thrombus removal 
was percutaneous mechanical thrombectomy which is a combination of 
mechanical and thrombolytic therapy (pharmacomechanical thrombol-
ysis) using dedicated percutaneous thrombectomy devices (PTDs). This 
method can optimize the lytic impact and diminish thrombolytic time. 
In up to 4 years of follow-up, the success rate for this combination was 
up to 90%, with an 86 percent limb salvage rate and a 58 percent 
primary patency rate. Mechanical thrombectomy has several advantag-
es, including a shorter procedure duration and the ability to be used as 
a monotherapy when thrombolysis is contraindicated or in combination 
with a low-dose thrombolytic in cases with high bleeding risk. The 
latter could also signify a lesser risk of hemorrhagic complications.8 In 
our case, this could be the best management for the patient to reduce 
the bleeding risk while optimizing the thrombus removal procedure.
 Despite prompt management, complications among ALI 
patients still high with 30-day mortality and amputation rates are 
between 10 and 15%. Other complications that can be experienced 
among ALI patients were myocardial infarction, deterioration in renal 
function, and respiratory complications that can increase in-hospital 
morbidity.4 Meanwhile, the complication might arise from the 
procedure of catheter-directed thrombolysis, such as major bleeding 
(intracerebral hemorrhage, intestinal bleeding, or puncture site 
bleeding requiring surgical intervention) and in-hospital death.8,12
Figure 1. Management of acute limb ischemia5
CTA = computed tomography angiography; DSA = digital subtraction angiography; DUS = Doppler ultrasound
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 Some factors could predict the result of catheter-directed 
thrombolysis and were associated with a poorer outcome like atrial 
fibrillation, older age over than 75 years old, history of previous bypass 
graft in ipsilateral limb, hypercholesterolemia, peripheral arterial 
disease, and prolonged duration of symptoms.13
4. Conclusion
 Acute limb ischemia is caused by a sudden diminish in 
arterial limb perfusion as a 6P’s was a common symptom due to a 
decrease in blood supply. And ALI is considered when the symptom 
duration is less than two weeks. Meanwhile, bilateral ALI caused by 
acute aortic occlusion is an uncommon condition needed precise 
treatment for life-saving and limb saving.
 As long as appropriate patient selection and procedure 
surveillance are achieved, percutaneous catheter-directed intra-arterial 
thrombolysis could be a safe and successful method for treating acute 
and subacute lower limb ischemia.
 Despite advances in diagnostic and treatment methods, ALI 
continues to be linked to an increase in major amputation and mortality 
rates in 20% of patients, owing to the presence of comorbidities such as 
other atherosclerotic illnesses.
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